ATE129635T1 - Zusammensetzungen für die krebstherapie. - Google Patents

Zusammensetzungen für die krebstherapie.

Info

Publication number: ATE129635T1
Authority: AT; Austria
Prior art keywords: cancer therapy; mhz; compositions; range; patient
Prior art date: 1991-09-06

Application number

AT92307687T

Other languages

English (en)

Inventor

John Alfred Gorton Holt

Original Assignee

John Alfred Gorton Holt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-09-06

Filing date

1992-08-21

Publication date

1995-11-15

1991-09-06 Priority claimed from GB919119081A external-priority patent/GB9119081D0/en

1992-08-21 Application filed by John Alfred Gorton Holt filed Critical John Alfred Gorton Holt

1995-11-15 Application granted granted Critical

1995-11-15 Publication of ATE129635T1 publication Critical patent/ATE129635T1/de

Links

238000011275 oncology therapy Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 abstract 2
FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 abstract 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
POYPKGFSZHXASD-WDSKDSINSA-N D-penicillamine disulfide Chemical compound OC(=O)[C@H](N)C(C)(C)SSC(C)(C)[C@@H](N)C(O)=O POYPKGFSZHXASD-WDSKDSINSA-N 0.000 abstract 1
229960003067 cystine Drugs 0.000 abstract 1
230000005670 electromagnetic radiation Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
231100000404 nontoxic agent Toxicity 0.000 abstract 1
150000008427 organic disulfides Chemical class 0.000 abstract 1
239000007800 oxidant agent Substances 0.000 abstract 1
125000005555 sulfoximide group Chemical group 0.000 abstract 1
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Radiation-Therapy Devices (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT92307687T 1991-09-06 1992-08-21 Zusammensetzungen für die krebstherapie. ATE129635T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919119081A GB9119081D0 (en)	1991-09-06	1991-09-06	Cancer therapy and compositions for use therein
GB929211396A GB9211396D0 (en)	1991-09-06	1992-05-29	Cancer therapy and compositions for use therein

Publications (1)

Publication Number	Publication Date
ATE129635T1 true ATE129635T1 (de)	1995-11-15

Family

ID=26299507

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92307687T ATE129635T1 (de)	1991-09-06	1992-08-21	Zusammensetzungen für die krebstherapie.

Country Status (7)

Country	Link
EP (1)	EP0531031B1 (de)
JP (1)	JPH07179336A (de)
AT (1)	ATE129635T1 (de)
AU (1)	AU643156B2 (de)
DE (1)	DE69205776T2 (de)
DK (1)	DK0531031T3 (de)
NZ (1)	NZ244141A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9303854D0 (en) *	1993-02-25	1993-04-14	Holt John A G	Method for enhancing t-cell count
GB9419061D0 (en) *	1994-09-20	1994-11-09	Holt John A G	Therapeutic methods and compositions for use therein
GB9617346D0 (en) *	1996-08-19	1996-10-02	Holt John A G	Therapeutic methods and compositions for use therein

1992
- 1992-08-21 AT AT92307687T patent/ATE129635T1/de not_active IP Right Cessation
- 1992-08-21 DE DE69205776T patent/DE69205776T2/de not_active Expired - Fee Related
- 1992-08-21 EP EP92307687A patent/EP0531031B1/de not_active Expired - Lifetime
- 1992-08-21 DK DK92307687.1T patent/DK0531031T3/da active
- 1992-08-28 NZ NZ244141A patent/NZ244141A/en not_active IP Right Cessation
- 1992-09-02 JP JP4234893A patent/JPH07179336A/ja not_active Withdrawn
- 1992-09-02 AU AU22090/92A patent/AU643156B2/en not_active Expired

Also Published As

Publication number	Publication date
AU643156B2 (en)	1993-11-04
JPH07179336A (ja)	1995-07-18
DE69205776T2 (de)	1996-04-25
EP0531031A1 (de)	1993-03-10
EP0531031B1 (de)	1995-11-02
DK0531031T3 (da)	1996-02-05
AU2209092A (en)	1993-04-08
DE69205776D1 (de)	1995-12-07
NZ244141A (en)	1993-12-23

Similar Documents

Publication	Publication Date	Title
ATE207355T1 (de)	2001-11-15	Behandlung von hyperproliferativen gefässerkrankungen
IT1198728B (it)	1988-12-21	Testa di applicazione per il trattamento elettromagnetico di una regione del corpo malata od offesa
ATE340590T1 (de)	2006-10-15	Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DE69201128D1 (de)	1995-02-16	Behandlung von neoplastischen krankenheiten mit interleukin-10.
ATE331703T1 (de)	2006-07-15	Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln
ES2033021T3 (es)	1996-07-16	Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
SE7902742L (sv)	1979-09-29	Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
ATE129635T1 (de)	1995-11-15	Zusammensetzungen für die krebstherapie.
IL83775A0 (en)	1988-02-29	Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
DE69110779D1 (de)	1995-08-03	Schilddrüsenhormone zur kardialen behandlung.
NZ242748A (en)	1995-01-27	Compositions containing a pseudocatalase for treating depigmentation disorders
SE8605503D0 (sv)	1986-12-19	Novel medicinal use
SE8102161L (sv)	1981-10-08	"3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
HUT70757A (en)	1995-10-30	Pharmaceutical compositions for treating skin disorders
ATE428438T1 (de)	2009-05-15	Tcf-ii enthaltende medizinische zusammensetzung
ATE215826T1 (de)	2002-04-15	Karzinostatisches mittel für hormontherapie, das dienogest als wirksamer bestandteil enthält
DE69518375D1 (de)	2000-09-21	Verwendung von nicht toxischen Cystein-Sulfoxid-Derivaten für die Behandlung von Krebs
ATE236881T1 (de)	2003-04-15	Durch strahlung aktivierte cytotoxin therapie
GB8921516D0 (en)	1989-11-08	Medicaments
SE8303729D0 (sv)	1983-06-29	Terapeutiskt medel for behandling av allergiska sjukdomstillstand, immunkomplexsjukdomar och tumorer
KR890017363A (ko)	1989-12-15	스트로빌루린 유도체, 이들의 제법 및 용도
JPS5750916A (en)	1982-03-25	Carcinostatic agent
SE8306384L (sv)	1984-05-21	Farmaceutisk komposition
ES2141114T3 (es)	2000-03-16	Bistriazenos utilizados como agentes quimioterapeuticos.
JPS5244241A (en)	1977-04-07	Prophylactic and therapeutic agents for mycoplasmal diseases

Legal Events

Date	Code	Title	Description
1996-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties